NASDAQ: STRRStar Equity Holdings Inc Stock
$1.83-0.06 (-3.17%)
Updated Apr 17, 2025
STRR Price
$1.83
Fair Value Price
N/A
Market Cap
$5.87M
52 Week Low
$1.81
52 Week High
$5.35
P/E
-0.55x
P/B
0.11x
P/S
0.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$53.36M
Earnings
-$10.44M
Gross Margin
20.7%
Operating Margin
-20.26%
Profit Margin
-23.4%
Debt to Equity
0.53
Operating Cash Flow
-$5M
Beta
0.77
Next Earnings
May 19, 2025
Ex-Dividend
N/A
Next Dividend
N/A
STRR Overview
Star Equity Holdings, Inc. provides healthcare solutions in the United States and internationally. It operates through four segments: Diagnostic Services, Diagnostic Imaging, Construction, and Investments. It offers imaging services primarily to cardiologists, internal medicine physicians, and family practice doctors; and imaging systems, including nuclear cardiac and general purpose nuclear imaging systems to physician offices and hospitals. The company also develops, sells, and maintains solid-state gamma cameras; and provides camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine STRR's potential to beat the market
- STRR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
STRR
RankedUnranked of 45
RankedUnranked of 45
Be the first to know about important STRR news, forecast changes, insider trades & much more!
STRR News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STRR scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STRR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STRR is good value based on its book value relative to its share price (0.11x), compared to the US Diagnostics & Research industry average (3.26x)
P/B vs Industry Valuation
STRR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more STRR due diligence checks available for Premium users.
Valuation
STRR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.55x
Industry
36.04x
Market
27.98x
STRR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.11x
Industry
3.26x
STRR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STRR's financial health
Profit margin
Revenue
$17.1M
Net Income
-$2.5M
Profit Margin
-17.5%
STRR's Earnings (EBIT) of -$10.81M... subscribe to Premium to read more.
Interest Coverage Financials
STRR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$83.0M
Liabilities
$28.7M
Debt to equity
0.53
STRR's short-term assets ($24.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STRR's short-term assets ($24.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STRR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
STRR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
$451.0k
Financing
-$2.0M
STRR's operating cash flow (-$5.18M)... subscribe to Premium to read more.
Debt Coverage Financials
STRR vs Diagnostic & Research Stocks
Star Equity Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.